Ventricular tachycardia is a condition, wherein the pulse rate is more than 100 beats per minute with minimum three continuous irregular heartbeats.
Patients suffering from cardiomyopathy, myocarditis, or valvular heart disease are at a higher risk of developing ventricular tachycardia.
Major reasons for ventricular tachycardia are changes in pH values, changes in blood chemistry, and lack of oxygen.
If left untreated, it leads to ventricular fibrillation (a leading cause of cardiac death).Request Brochure – https://www.transparencymarketresearch.com/sample/sample.php?flag=B_id=34034 Diagnostic techniques such as continuous ambulatory electrocardiogram, intra-cardiac electrophysiology study (EPS), electrocardiogram (ECG), loop recorder, and blood tests are utilized for confirming ventricular tachycardia.
The emergency segment has been sub-segmented into cardiopulmonary resuscitation (CPR), electric defibrillation (electric shock), and anti-arrhythmic medications (such as procinamide, lidocaine, amiodarone, and solatol that are injected through vein).
Furthermore, advancements in technology and improvements in existing treatment therapies are anticipated to fuel the ventricular tachycardia market during the forecast period.
Ventricular tachycardia is a condition, wherein the pulse rate is more than 100 beats per minute with minimum three continuous irregular heartbeats.
Patients suffering from cardiomyopathy, myocarditis, or valvular heart disease are at a higher risk of developing ventricular tachycardia.
Major reasons for ventricular tachycardia are changes in pH values, changes in blood chemistry, and lack of oxygen.
If left untreated, it leads to ventricular fibrillation (a leading cause of cardiac death).Request Brochure – https://www.transparencymarketresearch.com/sample/sample.php?flag=B_id=34034Diagnostic techniques such as continuous ambulatory electrocardiogram, intra-cardiac electrophysiology study (EPS), electrocardiogram (ECG), loop recorder, and blood tests are utilized for confirming ventricular tachycardia.
The emergency segment has been sub-segmented into cardiopulmonary resuscitation (CPR), electric defibrillation (electric shock), and anti-arrhythmic medications (such as procinamide, lidocaine, amiodarone, and solatol that are injected through vein).
Furthermore, advancements in technology and improvements in existing treatment therapies are anticipated to fuel the ventricular tachycardia market during the forecast period.
Paroxysmal Atrial Tachycardia Market by Type (AV Nodal Re-Entrant Tachycardia (AVNRT), AV Reciprocating Tachycardia (AVRT)), Diagnosis (ECG, Echocardiogram) Treatment (Calcium Channel Blockers, Digoxin), End User - Global forecast till 2023 The report presents a detailed analysis of Paroxysmal Atrial Tachycardia Market by Type by providing readers with a comprehensive overview of the market’s historical trajectory.
The leading drivers and restraints affecting the global prostate cancer market are assessed in detail in the report.
The historical impact of these drivers and restraints is analyzed in context of the current impact of these factors and projections are made for the likely impact of these drivers and restraints over the forecast period.
Major Key Players To gain a substantially large competitive advantage, these players incorporate strategic initiatives such as mergers & acquisitions, collaboration, expansion, and product launch.
Following are Some of the Top Players, Abbott Laboratories, Reliant Pharmaceuticals, BIOTRONIK SE & Co. KG, Boston Scientific Corporation, GlaxoSmithKline plc, GE Healthcare, Glenmark Pharmaceuticals, Koninklijke Philips N.V., ANI Pharmaceuticals, Inc., Medtronic, Inc., Microport Scientific Corporation, St. Jude Medical, Inc., and Siemens AG and others.
Paroxysmal Atrial Tachycardia Market by Type report offers insights into the leading market players and presents an assessment of their current market position.
Every year the event is being organized by the Arrhythmia Alliance (incorporating a team of patients, charities and professionals).
Also Read :Hypertension (High Blood Pressure) - The Silent KillerSome unknown facts about Arrhythmia:1 out of 2 people experience syncope at least once in their lifetime.On an average about 39% of children and 30% of adults are misdiagnosed with epilepsy when they have the underlying, potentially fatal arrhythmia.Sudden cardiac death is the number one killer in the world.
What is Heart Arrhythmia?Heart Arrhythmia is a disorder affecting the rhythm of the heart beat.
In various cases heart arrhythmia can lead to death but if the disorder is diagnosed properly and early it can help the person to lead a healthy life.Major types of arrhythmia are:Atrial Fibrillation (AF): Atrial Fibrillation is one of the most common types of heart arrhythmia.
Under this condition the heart beats irregularly and faster than normal heart beat.Supraventricular Tachycardia: under this condition the episodes of abnormally fast heart rate are at rest.Bradycardia: in Bradycardia arrhythmia the heart beats more slowly as compared to the normal heartbeat rate.Heart Block: in this situation the heart beats very slowly in comparison to normal heart beat and thus lead people to collapse.Ventricular Fibrillation: ventricular fibrillation is a rare, rapid and disorganized heartbeat rhythm which immediately leads to loss of consciousness and thus sudden death if there is no immediate treatment provided.Also Read : You are never too young or too Healthy to have a Heart AttackSymptoms of Arrhythmia:There are certain cases where there are no symptoms of arrhythmia as at times it can be silent.
Some common symptoms of arrhythmia are mentioned below:Extreme level of tiredness or fatigueDizzinessLight- headednessNear fainting spells or faintingPounding or rapid heartbeatShortness of breathPain in the chestIn extreme cases, collapse and sudden cardiac arrest happensA doctor is able to detect an irregular heartbeat with the help of a physical examination.
Summary Latest Pharmaceutical and Healthcare disease pipeline guide Ventricular Tachycardia - Pipeline Review, H1 2020, provides an overview of the Ventricular Tachycardia (Cardiovascular) pipeline landscape.
Causes include cardiomyopathy, ischemic heart disease and heart failure.
Report Highlights Pharmaceutical and Healthcare latest pipeline guide Ventricular Tachycardia - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Ventricular Tachycardia (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 5 and 3 respectively.
Ventricular Tachycardia (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
The guide is built using data and information sourced from We are proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Supraventricular tachycardia is a condition where there is a rapid increase in the heart rate that is caused by electrical impulses originating above the heart.
Paroxysmal supraventricular tachycardia, also known as PSVT, is a condition wherein the patient shows an irregularity in heart beating.
A normal heart beats between 60 to 100 beats per minute, but the heart rate of a person suffering from paroxysmal supraventricular tachycardia during an episode may exceed 150–200 beats per minute.The prevalence of Paroxysmal Supraventricular Tachycardia (PSVT) is unknown but is projected to be around several cases per thousand persons.
Moreover, some arrhythmias may lead to more serious medical problems such as sudden stroke or cardiac arrest.The global Paroxysmal Supraventricular Tachycardia (PSVT) market is expected to register a CAGR of approximately 6.50% during the forecast period, 2017–2023.SegmentationThe global Paroxysmal Supraventricular Tachycardia (PSVT) market is segmented on the basis of type, diagnosis, treatment, and end-user.On the basis of type, the global Paroxysmal Supraventricular Tachycardia (PSVT) market is segmented into AV Nodal Re-Entrant Tachycardia (AVNRT), AV Reciprocating Tachycardia (AVRT), Paroxysmal Atrial Tachycardia (PAT), and Wolff-Parkinson-White Syndrome (WPW).On the basis of diagnosis, the Global Paroxysmal Supraventricular Tachycardia (PSVT) market is classified into Electrophysiology Study (EPS), stress test, cardiac catheterization, coronary angiography, Electrocardiogram (ECG), echocardiogram, Holter monitor, event monitor, implantable monitor, lab tests, and others.
Lab tests are further classified into blood test, urine test, and others.On the basis of treatment, the global Paroxysmal Supraventricular Tachycardia (PSVT) market is classified into physical maneuvers, medications, catheter ablation, pacemaker, and cardioversion.
The antiarrhythmic medication is divided into sotalol, amiodarone, amiodarone, flecainide, propafenone, and adenosine.On the basis of end-user, the global Paroxysmal Supraventricular Tachycardia (PSVT) market is classified into hospitals and clinics, diagnostic centers, medical research centers, and others.Regional AnalysisThe global Paroxysmal Supraventricular Tachycardia (PSVT) market consists of four major regions, namely, the Americas, Europe, Asia Pacific, and the Middle East and Africa.The Americas dominates the market owing to the key players domiciled in these regions coupled with the increasing incidences of stroke, raising awareness among people, and increasing healthcare expenditure.
Market HighlightsTachycardia is a common type of heart disorder, which results in a faster heartbeat.
Tachycardia can be caused due to various conditions such as heart diseases including coronary artery disease, drinking large amounts of alcohol, and medical conditions such as thyroid disease and certain lung diseases.GET FREESAMPLE COPY @ https://www.marketresearchfuture.com/sample_request/5883Global Tachycardia Market is expected to grow at a CAGR of 6.5% during the forecast period.Regional AnalysisThe Americas dominates the global tachycardia market owing to the increasing aging population, which eventually leads to increase in patient population.
Additionally, increasing obesity rates along with increasing cardiovascular disorder rates is likely to enhance the growth of tachycardia in the North American region.
According to the American Heart Association, 31% of deaths in the U.S. were due to cardiovascular disorders.
Similarly, according to the National Institute on Alcohol Abuse and Alcoholism, in 2015 around 15.1 million adults of 18 and above in the U.S. had alcohol use disorder.
These factors are likely to drive the growth of the tachycardia market.Asia Pacific is the fastest growing market for tachycardia whose growth is attributed to the increasing population and increasing standard of living.
Market ScenarioTachycardia is a common type of heart disorder, which results in a faster heartbeat.
Tachycardia can be caused due to various conditions such as heart diseases including coronary artery disease, drinking large amounts of alcohol, and medical conditions such as thyroid disease and certain lung diseases.The global tachycardia market is majorly driven by the high prevalence of cardiovascular diseases, high consumption of alcohol, and increasing lung disorders.
Additionally, factors such as increasing approvals for vascular closure devices, government initiatives and support, increasing demand for advanced treatment, increasing research and clinical trials for tachycardia, and growing market players offering newer products are likely to drive the market.View Reports Sample @ https://www.marketresearchfuture.com/sample_request/5883 Factors that are likely to hamper the growth of the market are the high cost of the treatment and lack of awareness.The Global Tachycardia Market is expected to grow at a CAGR of 6.5% during the forecast period.Intended AudiencePharmaceutical Manufacturers and SuppliersMedical Research LaboratoriesResearch and Development (R) CompaniesMarket Research and Consulting Service ProvidersPotential InvestorsSegments The global tachycardia market is segmented on the basis of type, treatment, diagnosis, and end-user.On the basis of type, the market is segmented into atrial fibrillation, atrial flutter, supraventricular tachycardia, ventricular tachycardia, ventricular fibrillation, and tachy-brady syndrome.
On the basis of imaging tests, it is further sub-segmented into echocardiogram, MRI, CT scan, coronary angiogram, and chest X-ray.On the basis of end-user, the market is segmented into ambulatory surgical centers, specialty centers, and hospitals and clinics.Regional AnalysisThe North American tachycardia market is a growing market in the Americas region.
The increasing number of alcohol consumption and rising prevalence of cardiovascular rates are likely to enhance the growth of vascular closure devices.
Additionally, the increasing need for minimally invasive procedures, growing healthcare expenditure, and the rising demand for technologically advanced treatments and products along with the rising government support are likely to enhance the growth of the tachycardia market in North America.Europe is the second largest market and holds a healthy share in the global tachycardia market.
Market HighlightsTachycardia is a common type of heart disorder, which results in a faster heartbeat.
Tachycardia can be caused due to various conditions such as heart diseases including coronary artery disease, drinking large amounts of alcohol, and medical conditions such as thyroid disease and certain lung diseases.GET FREESAMPLE COPY @ https://www.marketresearchfuture.com/sample_request/5883Global Tachycardia Market is expected to grow at a CAGR of 6.5% during the forecast period.Regional AnalysisThe Americas dominates the global tachycardia market owing to the increasing aging population, which eventually leads to increase in patient population.
Additionally, increasing obesity rates along with increasing cardiovascular disorder rates is likely to enhance the growth of tachycardia in the North American region.
According to the American Heart Association, 31% of deaths in the U.S. were due to cardiovascular disorders.
Similarly, according to the National Institute on Alcohol Abuse and Alcoholism, in 2015 around 15.1 million adults of 18 and above in the U.S. had alcohol use disorder.
These factors are likely to drive the growth of the tachycardia market.Asia Pacific is the fastest growing market for tachycardia whose growth is attributed to the increasing population and increasing standard of living.
Ventricular tachycardia is a condition, wherein the pulse rate is more than 100 beats per minute with minimum three continuous irregular heartbeats.
Patients suffering from cardiomyopathy, myocarditis, or valvular heart disease are at a higher risk of developing ventricular tachycardia.
Major reasons for ventricular tachycardia are changes in pH values, changes in blood chemistry, and lack of oxygen.
If left untreated, it leads to ventricular fibrillation (a leading cause of cardiac death).Request Brochure – https://www.transparencymarketresearch.com/sample/sample.php?flag=B_id=34034Diagnostic techniques such as continuous ambulatory electrocardiogram, intra-cardiac electrophysiology study (EPS), electrocardiogram (ECG), loop recorder, and blood tests are utilized for confirming ventricular tachycardia.
The emergency segment has been sub-segmented into cardiopulmonary resuscitation (CPR), electric defibrillation (electric shock), and anti-arrhythmic medications (such as procinamide, lidocaine, amiodarone, and solatol that are injected through vein).
Furthermore, advancements in technology and improvements in existing treatment therapies are anticipated to fuel the ventricular tachycardia market during the forecast period.
Paroxysmal Atrial Tachycardia Market by Type (AV Nodal Re-Entrant Tachycardia (AVNRT), AV Reciprocating Tachycardia (AVRT)), Diagnosis (ECG, Echocardiogram) Treatment (Calcium Channel Blockers, Digoxin), End User - Global forecast till 2023 The report presents a detailed analysis of Paroxysmal Atrial Tachycardia Market by Type by providing readers with a comprehensive overview of the market’s historical trajectory.
The leading drivers and restraints affecting the global prostate cancer market are assessed in detail in the report.
The historical impact of these drivers and restraints is analyzed in context of the current impact of these factors and projections are made for the likely impact of these drivers and restraints over the forecast period.
Major Key Players To gain a substantially large competitive advantage, these players incorporate strategic initiatives such as mergers & acquisitions, collaboration, expansion, and product launch.
Following are Some of the Top Players, Abbott Laboratories, Reliant Pharmaceuticals, BIOTRONIK SE & Co. KG, Boston Scientific Corporation, GlaxoSmithKline plc, GE Healthcare, Glenmark Pharmaceuticals, Koninklijke Philips N.V., ANI Pharmaceuticals, Inc., Medtronic, Inc., Microport Scientific Corporation, St. Jude Medical, Inc., and Siemens AG and others.
Paroxysmal Atrial Tachycardia Market by Type report offers insights into the leading market players and presents an assessment of their current market position.
Every year the event is being organized by the Arrhythmia Alliance (incorporating a team of patients, charities and professionals).
Also Read :Hypertension (High Blood Pressure) - The Silent KillerSome unknown facts about Arrhythmia:1 out of 2 people experience syncope at least once in their lifetime.On an average about 39% of children and 30% of adults are misdiagnosed with epilepsy when they have the underlying, potentially fatal arrhythmia.Sudden cardiac death is the number one killer in the world.
What is Heart Arrhythmia?Heart Arrhythmia is a disorder affecting the rhythm of the heart beat.
In various cases heart arrhythmia can lead to death but if the disorder is diagnosed properly and early it can help the person to lead a healthy life.Major types of arrhythmia are:Atrial Fibrillation (AF): Atrial Fibrillation is one of the most common types of heart arrhythmia.
Under this condition the heart beats irregularly and faster than normal heart beat.Supraventricular Tachycardia: under this condition the episodes of abnormally fast heart rate are at rest.Bradycardia: in Bradycardia arrhythmia the heart beats more slowly as compared to the normal heartbeat rate.Heart Block: in this situation the heart beats very slowly in comparison to normal heart beat and thus lead people to collapse.Ventricular Fibrillation: ventricular fibrillation is a rare, rapid and disorganized heartbeat rhythm which immediately leads to loss of consciousness and thus sudden death if there is no immediate treatment provided.Also Read : You are never too young or too Healthy to have a Heart AttackSymptoms of Arrhythmia:There are certain cases where there are no symptoms of arrhythmia as at times it can be silent.
Some common symptoms of arrhythmia are mentioned below:Extreme level of tiredness or fatigueDizzinessLight- headednessNear fainting spells or faintingPounding or rapid heartbeatShortness of breathPain in the chestIn extreme cases, collapse and sudden cardiac arrest happensA doctor is able to detect an irregular heartbeat with the help of a physical examination.
Supraventricular tachycardia is a condition where there is a rapid increase in the heart rate that is caused by electrical impulses originating above the heart.
Paroxysmal supraventricular tachycardia, also known as PSVT, is a condition wherein the patient shows an irregularity in heart beating.
A normal heart beats between 60 to 100 beats per minute, but the heart rate of a person suffering from paroxysmal supraventricular tachycardia during an episode may exceed 150–200 beats per minute.The prevalence of Paroxysmal Supraventricular Tachycardia (PSVT) is unknown but is projected to be around several cases per thousand persons.
Moreover, some arrhythmias may lead to more serious medical problems such as sudden stroke or cardiac arrest.The global Paroxysmal Supraventricular Tachycardia (PSVT) market is expected to register a CAGR of approximately 6.50% during the forecast period, 2017–2023.SegmentationThe global Paroxysmal Supraventricular Tachycardia (PSVT) market is segmented on the basis of type, diagnosis, treatment, and end-user.On the basis of type, the global Paroxysmal Supraventricular Tachycardia (PSVT) market is segmented into AV Nodal Re-Entrant Tachycardia (AVNRT), AV Reciprocating Tachycardia (AVRT), Paroxysmal Atrial Tachycardia (PAT), and Wolff-Parkinson-White Syndrome (WPW).On the basis of diagnosis, the Global Paroxysmal Supraventricular Tachycardia (PSVT) market is classified into Electrophysiology Study (EPS), stress test, cardiac catheterization, coronary angiography, Electrocardiogram (ECG), echocardiogram, Holter monitor, event monitor, implantable monitor, lab tests, and others.
Lab tests are further classified into blood test, urine test, and others.On the basis of treatment, the global Paroxysmal Supraventricular Tachycardia (PSVT) market is classified into physical maneuvers, medications, catheter ablation, pacemaker, and cardioversion.
The antiarrhythmic medication is divided into sotalol, amiodarone, amiodarone, flecainide, propafenone, and adenosine.On the basis of end-user, the global Paroxysmal Supraventricular Tachycardia (PSVT) market is classified into hospitals and clinics, diagnostic centers, medical research centers, and others.Regional AnalysisThe global Paroxysmal Supraventricular Tachycardia (PSVT) market consists of four major regions, namely, the Americas, Europe, Asia Pacific, and the Middle East and Africa.The Americas dominates the market owing to the key players domiciled in these regions coupled with the increasing incidences of stroke, raising awareness among people, and increasing healthcare expenditure.
Market ScenarioTachycardia is a common type of heart disorder, which results in a faster heartbeat.
Tachycardia can be caused due to various conditions such as heart diseases including coronary artery disease, drinking large amounts of alcohol, and medical conditions such as thyroid disease and certain lung diseases.The global tachycardia market is majorly driven by the high prevalence of cardiovascular diseases, high consumption of alcohol, and increasing lung disorders.
Additionally, factors such as increasing approvals for vascular closure devices, government initiatives and support, increasing demand for advanced treatment, increasing research and clinical trials for tachycardia, and growing market players offering newer products are likely to drive the market.View Reports Sample @ https://www.marketresearchfuture.com/sample_request/5883 Factors that are likely to hamper the growth of the market are the high cost of the treatment and lack of awareness.The Global Tachycardia Market is expected to grow at a CAGR of 6.5% during the forecast period.Intended AudiencePharmaceutical Manufacturers and SuppliersMedical Research LaboratoriesResearch and Development (R) CompaniesMarket Research and Consulting Service ProvidersPotential InvestorsSegments The global tachycardia market is segmented on the basis of type, treatment, diagnosis, and end-user.On the basis of type, the market is segmented into atrial fibrillation, atrial flutter, supraventricular tachycardia, ventricular tachycardia, ventricular fibrillation, and tachy-brady syndrome.
On the basis of imaging tests, it is further sub-segmented into echocardiogram, MRI, CT scan, coronary angiogram, and chest X-ray.On the basis of end-user, the market is segmented into ambulatory surgical centers, specialty centers, and hospitals and clinics.Regional AnalysisThe North American tachycardia market is a growing market in the Americas region.
The increasing number of alcohol consumption and rising prevalence of cardiovascular rates are likely to enhance the growth of vascular closure devices.
Additionally, the increasing need for minimally invasive procedures, growing healthcare expenditure, and the rising demand for technologically advanced treatments and products along with the rising government support are likely to enhance the growth of the tachycardia market in North America.Europe is the second largest market and holds a healthy share in the global tachycardia market.
Ventricular tachycardia is a condition, wherein the pulse rate is more than 100 beats per minute with minimum three continuous irregular heartbeats.
Patients suffering from cardiomyopathy, myocarditis, or valvular heart disease are at a higher risk of developing ventricular tachycardia.
Major reasons for ventricular tachycardia are changes in pH values, changes in blood chemistry, and lack of oxygen.
If left untreated, it leads to ventricular fibrillation (a leading cause of cardiac death).Request Brochure – https://www.transparencymarketresearch.com/sample/sample.php?flag=B_id=34034 Diagnostic techniques such as continuous ambulatory electrocardiogram, intra-cardiac electrophysiology study (EPS), electrocardiogram (ECG), loop recorder, and blood tests are utilized for confirming ventricular tachycardia.
The emergency segment has been sub-segmented into cardiopulmonary resuscitation (CPR), electric defibrillation (electric shock), and anti-arrhythmic medications (such as procinamide, lidocaine, amiodarone, and solatol that are injected through vein).
Furthermore, advancements in technology and improvements in existing treatment therapies are anticipated to fuel the ventricular tachycardia market during the forecast period.
Summary Latest Pharmaceutical and Healthcare disease pipeline guide Ventricular Tachycardia - Pipeline Review, H1 2020, provides an overview of the Ventricular Tachycardia (Cardiovascular) pipeline landscape.
Causes include cardiomyopathy, ischemic heart disease and heart failure.
Report Highlights Pharmaceutical and Healthcare latest pipeline guide Ventricular Tachycardia - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Ventricular Tachycardia (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 5 and 3 respectively.
Ventricular Tachycardia (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
The guide is built using data and information sourced from We are proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Market HighlightsTachycardia is a common type of heart disorder, which results in a faster heartbeat.
Tachycardia can be caused due to various conditions such as heart diseases including coronary artery disease, drinking large amounts of alcohol, and medical conditions such as thyroid disease and certain lung diseases.GET FREESAMPLE COPY @ https://www.marketresearchfuture.com/sample_request/5883Global Tachycardia Market is expected to grow at a CAGR of 6.5% during the forecast period.Regional AnalysisThe Americas dominates the global tachycardia market owing to the increasing aging population, which eventually leads to increase in patient population.
Additionally, increasing obesity rates along with increasing cardiovascular disorder rates is likely to enhance the growth of tachycardia in the North American region.
According to the American Heart Association, 31% of deaths in the U.S. were due to cardiovascular disorders.
Similarly, according to the National Institute on Alcohol Abuse and Alcoholism, in 2015 around 15.1 million adults of 18 and above in the U.S. had alcohol use disorder.
These factors are likely to drive the growth of the tachycardia market.Asia Pacific is the fastest growing market for tachycardia whose growth is attributed to the increasing population and increasing standard of living.
Market HighlightsTachycardia is a common type of heart disorder, which results in a faster heartbeat.
Tachycardia can be caused due to various conditions such as heart diseases including coronary artery disease, drinking large amounts of alcohol, and medical conditions such as thyroid disease and certain lung diseases.GET FREESAMPLE COPY @ https://www.marketresearchfuture.com/sample_request/5883Global Tachycardia Market is expected to grow at a CAGR of 6.5% during the forecast period.Regional AnalysisThe Americas dominates the global tachycardia market owing to the increasing aging population, which eventually leads to increase in patient population.
Additionally, increasing obesity rates along with increasing cardiovascular disorder rates is likely to enhance the growth of tachycardia in the North American region.
According to the American Heart Association, 31% of deaths in the U.S. were due to cardiovascular disorders.
Similarly, according to the National Institute on Alcohol Abuse and Alcoholism, in 2015 around 15.1 million adults of 18 and above in the U.S. had alcohol use disorder.
These factors are likely to drive the growth of the tachycardia market.Asia Pacific is the fastest growing market for tachycardia whose growth is attributed to the increasing population and increasing standard of living.